Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France.
Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-Jaïs C, Castot A, Montastruc JL; French Network of Pharmacovigilance Centres. Caillet C, et al. Eur J Clin Pharmacol. 2011 Jun;67(6):649-51. doi: 10.1007/s00228-010-0961-8. Epub 2010 Dec 14. Eur J Clin Pharmacol. 2011. PMID: 21153631 No abstract available.
[National Campaign of Vaccination against the flu A (H1N1)v: National Follow-up of Pharmacovigilance].
Durrieu G, Caillet C, Lacroix I, Jacquet A, Faucher A, Ouaret S, Sommet A, Perault-Pochat MC, Kreft-Jaïs C, Castot A, Damase-Michel C, Montastruc JL; le réseau français des centres de pharmacovigilance. Durrieu G, et al. Therapie. 2011 Nov-Dec;66(6):527-40. doi: 10.2515/therapie/2011075. Epub 2011 Dec 21. Therapie. 2011. PMID: 22186078 Review. French.
First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A, Lapeyre-Mestre M, Montastruc JL; French Network of Pharmacovigilance Centres. Durrieu G, et al. Drug Saf. 2012 Oct 1;35(10):845-54. doi: 10.1007/BF03261980. Drug Saf. 2012. PMID: 22967189
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
Bénard-Laribière A, Miremont-Salamé G, Pérault-Pochat MC, Noize P, Haramburu F; EMIR Study Group on behalf of the French network of pharmacovigilance centres. Bénard-Laribière A, et al. Fundam Clin Pharmacol. 2015 Feb;29(1):106-11. doi: 10.1111/fcp.12088. Epub 2014 Sep 25. Fundam Clin Pharmacol. 2015. PMID: 24990220
Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population.
Hillaire-Buys D, Mousset M, Allouchery M, Azzouz B, Babin M, Bellet F, Béné J, Default A, Durrieu G, Géniaux H, Grandvuillemin A, Gras-Champel V, Jantzem H, Lambert A, Lepelley M, Massy N, Petitpain N, Rocher F, Sanchez-Pena P, Sassier M, Simon C, Triquet L, Valnet-Rabier MB, Veyrac G, Faillie JL, Zenut MC. Hillaire-Buys D, et al. Among authors: valnet rabier mb. Therapie. 2020 Sep-Oct;75(5):471-480. doi: 10.1016/j.therap.2019.08.001. Epub 2019 Oct 28. Therapie. 2020. PMID: 31732241
French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.
Lacroix C, Salvo F, Gras-Champel V, Gautier S, Massy N, Valnet-Rabier MB, Grandvuillemin A, Mounier C, Benkebil M, Pariente A, Jonville-Béra AP, Micallef J; French Network of Pharmacovigilance Centres. Lacroix C, et al. Among authors: valnet rabier mb. Therapie. 2021 Jul-Aug;76(4):297-303. doi: 10.1016/j.therap.2021.05.003. Epub 2021 May 7. Therapie. 2021. PMID: 34059351 Free PMC article.
50 results